{
}
Novartis is set to close the German biotech company Morphosys, impacting 330 jobs, as part of its strategy to integrate all portfolio activities into Novartis. The decision to shut down Morphosys sites in Germany and the U.S. by the end of 2025 was announced in November 2024.
Roche's phase 2b trial of prasinezumab, an anti-alpha-synuclein antibody partnered with Prothena, failed to meet its primary endpoint for treating early-stage Parkinson's disease, with a p value of 0.0657. However, Roche highlighted potential clinical efficacy in a subgroup receiving levodopa, showing a nominal p value of 0.0431. Despite the setbacks in alpha-synuclein targeting therapies, Roche plans to continue tracking patients and evaluate future steps after discussions with regulators.
Novartis is closing MorphoSys sites in the U.S. and Germany, resulting in 330 job losses, as part of a strategic shift following mixed trial results for the drug pelabresib. The company, which acquired MorphoSys for $2.9 billion, has delayed regulatory submission for the drug until at least 2027 due to the need for additional data. This move is part of a broader restructuring effort that has seen Novartis cut back significantly in recent years.
BioAge Labs and Novartis have entered a collaboration aimed at identifying novel targets for therapies addressing age-related diseases. As part of the agreement, BioAge will receive up to $20 million in upfront payments and research funding to support this initiative.
Novartis and AbbVie secured a legal victory against West Virginia's S.B. 325, which mandated drugmakers to distribute discounted drugs to unlimited pharmacies under the 340B Drug Pricing Program. The court found that the law obstructs federal objectives and imposes irreparable harm on the pharmaceutical industry, blocking its enforcement while the case proceeds. The ruling highlights the law's conflict with federal regulations, particularly regarding audits and penalties for non-compliance.
BioAge Labs has entered a multi-year partnership with Novartis to tackle age-related diseases, potentially worth up to $550 million. The collaboration will leverage BioAge's human longevity datasets and Novartis's expertise in exercise biology to discover new therapeutic targets and explore the biological mechanisms of aging. This agreement follows BioAge's recent IPO and the discontinuation of a phase 2 obesity trial due to safety concerns.
BioAge Labs shares surged 14% to $4.67 following a research collaboration with Novartis, potentially worth up to $550 million. The partnership will explore aging-related diseases and the impact of physical exercise on longevity, combining BioAge's datasets with Novartis's expertise. BioAge will receive initial funding and milestone payments, with both companies able to pursue novel targets identified during the collaboration.
BioAge stock surged 14% following the announcement of a research collaboration with Novartis. This partnership is expected to enhance BioAge's capabilities in developing therapies aimed at age-related diseases, signaling strong market confidence in the company's future prospects.
BioAge Labs has announced a multi-year collaboration with Novartis to discover novel therapeutic targets for age-related diseases, leveraging BioAge's extensive human longevity data and Novartis's expertise in exercise biology. The partnership includes up to $20 million in upfront payments and research funding, with potential future milestones totaling up to $530 million. This collaboration aims to explore the biological mechanisms of aging and the benefits of physical exercise to develop transformative therapies.
BioAge Labs has entered a multi-year collaboration with Novartis to discover novel therapeutic targets for age-related diseases, leveraging BioAge's extensive human longevity data and Novartis's expertise in exercise biology. The partnership could yield up to $550 million in funding and milestone payments, aiming to enhance treatment options for aging-related conditions.
Novartis AG
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
novartis to close morphosys affecting 330 jobs by end of 2025
11:20 19.12.2024
Roche reports phase 2b failure for Parkinson's treatment but sees potential benefits
10:31 19.12.2024
Novartis closes MorphoSys sites and lays off 330 amid drug development delays
01:00 19.12.2024
bioage and novartis collaborate to target age-related diseases
20:02 18.12.2024
court blocks west virginia law limiting drug distribution under 340b program
18:01 18.12.2024
novartis and bioage partner to tackle age-related diseases in major deal
United States Dollar
Novartis AG
Amgen Inc.
BioAge Labs, Inc.
Eli Lilly and Company
USA
CHE
Lai Peng Leong
Michaela Kneissel
Kristen Fortney
Show more
16:44 18.12.2024
bioage partners with novartis in research collaboration worth up to 550 million
16:37 18.12.2024
BioAge shares rise 14 percent following collaboration with Novartis
16:21 18.12.2024
bioage labs partners with novartis to target age-related diseases through research
15:11 18.12.2024
bioage labs and novartis collaborate to target age-related diseases through exercise biology
15:00 18.12.2024
Trending
Subcategory
Startups & Entrepreneurship
Industry Trends
Corporate News
Private Equity Deals
Retail and Consumer Goods
Supply Chain Management
Global Trade Developments
CEO Changes
Government Economic Policies
Corporate Social Responsibility
Industry Mergers & Acquisitions
Workplace Trends
Energy Sector Developments
Venture Capital Investments
Fintech Startups
Finance Mergers & Acquisitions
AI Innovations
Market Analysis and Predictions
Intellectual Property Laws
Central Bank Actions
Countries:
Companies:
Apple Inc.
NVIDIA Corporation
Google Inc.
Amazon.com, Inc.
Tesla, Inc.
Salesforce, Inc.
Garuda Aerospace Ltd.
Huawei Technologies CO. Ltd.
Bharti Airtel Ltd.
XPeng Inc.
Microsoft Corporation
Venturewave Capital NO.1 Ltd.
Semler Scientific, Inc.
TENCENT
Wipro Ltd
OpenAI ERC USD
Orange S.A.
IDBI Bank Limited
Standard Chartered Bank
LENOVO GROUP
Currencies:
United States Dollar
Indian Rupee
Chinese Yuan
Euro
Saudi Riyal
Japanese Yen
Malaysian Ringgit
British Pound Sterling
Mexican Peso
Brazilian Real
New Taiwan Dollar
Bahraini Dinar
Qatari Riyal
Pakistani Rupee
Kuwaiti Dinar
Vietnamese Đồng
South Korean Won
Algerian Dinar
People:
Donald Trump
Mark Zuckerberg
Bisrat Degefa
He Xiaopeng
Abdel Fattah El-Sisi
Anmol Singh Jaggi
Puneet Singh Jaggi
Sari Sabban
David Watkins
Simon Moon
Anas Algahtani
Matt Jones
Ayman Hamdan
Elon Musk
Allen Law
Xi Jinping
Anwar Hussain
Sultan Ibrahim ibni Sultan Iskandar
Prashant Joshi
Albinder Dhindsa